MYR Pharmaceuticals GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Burgwedel Germany (2010)
Status: Acquired by Gilead Sciences (2020)

Organization Overview

First Clinical Trial
2019
NCT03852433
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MYR GmbH

Active Ingredients

Drugs in Phase 3 Trials (1)

bulevirtide (2 trials)

Drugs in Phase 2 Trials (1)

interferon alpha-2a (roferon-a) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis D (Phase 3)

Hepatitis D, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2